David M. Weber - 31 Mar 2022 Form 4 Insider Report for ABIOMED INC

Role: CHIEF OPERATING OFFICER
Signature: /s/ Marc A. Began (by power of attorney)
Issuer symbol: N/A
Transactions as of: 31 Mar 2022
Net transactions value: -$2,550,000
Form type: 4
Filing time: 04 Apr 2022, 17:07:49 UTC
Previous filing: 18 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NASD	Common Stock, $.01 par value	Sale	$2,550,000	-7,500	-6.1%	$340.00^*	116,314	31 Mar 2022	Direct	F1, F2
holding	NASD	Common Stock, $.01 par value						15,497	31 Mar 2022	By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	NASD	Stock Option (right to buy)						10,000	31 Mar 2022	Common Stock	0	$66.25	Direct	F3, F4
holding	NASD	Stock Option (right to buy)						7,000	31 Mar 2022	Common Stock	0	$99.62	Direct	F4, F5
holding	NASD	Stock Option (right to buy)						8,000	31 Mar 2022	Common Stock	0	$134.51	Direct	F4, F5
holding	NASD	Stock Option (right to buy)						6,500	31 Mar 2022	Common Stock	0	$381.97	Direct	F4, F5
holding	NASD	Stock Option (right to buy)						6,000	31 Mar 2022	Common Stock	0	$266.39	Direct	F4, F5
holding	NASD	Stock Option (right to buy)						5,000	31 Mar 2022	Common Stock	0	$223.90	Direct	F4, F5
holding	NASD	Stock Option (right to buy)						4,969	31 Mar 2022	Common Stock	0	$283.88	Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sale of common stock pursuant to reporting owner's 10b5-1 plan.
F2	This price represents the sale price of the transactions on the reported date at $340.00. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
F3	Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
F4	These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
F5	Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.